The Association of Maternal HBB Pathogenic Variant Status and Fetal Fraction in Non-Invasive Prenatal Screening

Manesha Putra, MD1,2,3; Kristjan Eerik Kaseniit, MEng4; Melissa Ann Hicks, MS5; Dale Muzzey, PhD6; David Hackney, MD, MS1,3

1. University Hospital Cleveland Medical Center, Cleveland, OH 2. MetroHealth Medical Center, Cleveland, OH 3. Case Western Reserve University, Cleveland, OH 4. Myriad Genetics, Salt Lake City, UT 5. Detroit Medical Center University Laboratories, Detroit, MI

INTRODUCTION

- Hemoglobinopathy is associated with an increased risk for several conditions, such as renal medullary cancer, hematuria, renal papillary necrosis, splenic infarctions, and even sudden death.
- In addition, β-globin hemoglobinopathies may include structural hemoglobinopathy. This includes hemoglobin-S, which is associated with sickle-cell disease.
- Women affected with β-globin hemoglobinopathies have been observed to have lower fetal fraction on noninvasive prenatal screening (NIPS), possibly resulting from a higher rate of necrosis of maternal cells and associated increase in maternal cell-free DNA (cfDNA).

OBJECTIVES

To evaluate the clinical implications of NIPS for pregnant women with β-globin hemoglobinopathies, we evaluated fetal fraction and the NIPS "no-call" rate due to low fetal fraction in HBB pathogenic variant carriers and non-carriers.

For comparison, we also assessed pregnant women with α-globin hemoglobinopathies.

METHODS

STUDY DESIGN

- We retrospectively analyzed women tested in our laboratory from 2016-2019 who had both whole-genome sequencing NIPS and carrier screening that included hemoglobinopathies.
- A corrected fetal fraction was determined using multivariable linear regression to adjust for maternal age, gestational age, and BMI.
- NIPS “no-call” rates were calculated using a fetal fraction cut-off of 4%, where all samples with a fetal fraction <4% would be failed.
- Subgroup analyses were performed on the hemoglobin S-carriers and non-hemoglobin-S carriers.

COHORTS

- **Group 1** consisted of all women with NIPS who were carriers of the HBB gene hemoglobinopathies (Figure 1). This includes:
  - Structural hemoglobinopathy carriers (S, C, E trait)
  - Quantitative hemoglobinopathy carriers (β-thalassemia minor and trait)
- **Group 2** consisted of women with NIPS who were also carriers for α-globin (HBA1/HBA2) gene(s) hemoglobinopathies, which included α-thalassemia silent carriers and traits (Figure 1).
- Both groups were compared to women who were not carriers for HBB or HBA1/HBA2 hemoglobinopathies.
- All women affected by HBB and HBA1/HBA2 hemoglobinopathies were excluded from the study.


RESULTS

- The corrected fetal fractions for HBB carriers was distinct from non-carriers, with a shift toward lower fetal fraction (Figure 2A).
  - The same was observed for hemoglobin-S carriers (Figure 2A inset).
- If a standard fetal fraction cut-off of 4% had been used during NIPS testing, the no-call rate among HBB carriers would have been 1.8-times higher than non-carriers (7.9% versus 4.4%; Figure 2B).
- When HBA1/HBA2 carriers were assessed, there were no differences in the corrected fetal fraction or the expected no-call rates for carriers and non-carriers (Figure 3).
  - This demonstrates that the impact on fetal fraction is specific to β-globin hemoglobinopathies.

CONCLUSIONS

- **HBB** carriers had lower fetal fraction and a higher potential "no-call" rate than non-carriers with a similar effect seen among women with sickle cell trait.
- There were no differences in fetal fraction level between HBA1/HBA2 carriers and non-carriers.
- This is the first study to describe the association of HBB gene pathogenic variant carriers and lower fetal fraction level.
- Pretest counseling should be adjusted to indicate the increased potential of no-call results in this population.